To discuss the implications of updated FDA labeling on menopausal hormone therapy (MHT) and the need for improved clinical practices, emphasizing the responsibility of clinicians.
Key Findings:
MHT use declined from over 20% to under 5% after the Women’s Health Initiative, highlighting the need for updated practices.
Updated FDA labeling reflects a favorable benefit-risk profile for MHT when initiated early.
Gaps exist in menopause education and clinical practice, particularly among non-specialized clinicians, affecting patient access to care.
Interpretation:
The updated FDA guidance provides a chance for clinicians to reassess their practices and improve care for menopausal women, emphasizing the importance of individualized treatment plans.
Limitations:
Access to MHT varies by insurance coverage, and newer treatment options may face authorization hurdles, impacting patient care.
Not all clinicians may be equipped or trained to implement menopause symptom screening effectively, which can hinder proper treatment.
Conclusion:
Clinicians are encouraged to integrate menopause symptom assessment and treatment into their practice, supported by continuing education and evidence-based resources.
